Targeting RAS signalling pathways in cancer therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12509763.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The RAS proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. They are aberrant in most human tumours due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signalling components. Rational therapies that target the RAS pathways might inhibit tumour growth, survival and spread. Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.
Medical subject headings
- Antineoplastic Agents
- GTP Phosphohydrolase Activators
- Genes, ras
- Neoplasms
- Signal Transduction
- ras Proteins